Should I buy or sell Innoviva stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INVA shares. View INVA analyst ratings or view top-rated stocks .

What is Innoviva's stock price target for 2024?

1 brokers have issued twelve-month price targets for Innoviva's shares. Their INVA share price targets range from $22.50 to $22.50. On average, they anticipate the company's stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 55.4% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts .

How have INVA shares performed in 2024?

Innoviva's stock was trading at $16.04 at the beginning of 2024. Since then, INVA shares have decreased by 9.7% and is now trading at $14.48. View the best growth stocks for 2024 here .

Are investors shorting Innoviva?

Innoviva saw a drop in short interest in March. As of March 31st, there was short interest totaling 11,330,000 shares, a drop of 13.0% from the March 15th total of 13,020,000 shares. Based on an average daily trading volume, of 681,300 shares, the days-to-cover ratio is presently 16.6 days. Approximately 18.2% of the shares of the stock are sold short. View Innoviva's Short Interest .

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our INVA earnings forecast .

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Thursday, February, 29th. The biotechnology company reported $0.76 earnings per share for the quarter. The biotechnology company earned $85.84 million during the quarter. Innoviva had a net margin of 57.89% and a trailing twelve-month return on equity of 30.37%.

What ETFs hold Innoviva's stock?

ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV) , Invesco Pharmaceuticals ETF (PJP) , ETC 6 Meridian Small Cap Equity ETF (SIXS) , Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) , Harbor Health Care ETF (MEDI) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco S&P SmallCap Health Care ETF (PSCH) .

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO) , Gilead Sciences (GILD) , Exelixis (EXEL) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Pfizer (PFE) , Vertex Pharmaceuticals (VRTX) , NVIDIA (NVDA) , OPKO Health (OPK) and Sorrento Therapeutics (SRNE) .

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.22%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alexander J Denner, George Bickerstaff , Innoviva, Inc, Marianne Zhen , Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends .

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INVA

Innoviva (INVA) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free INVA Stock Alerts

$14.60

+0.12 (+0.83%)

(As of 10:33 AM ET)

Compare

Today's Range: $14.44
▼
$14.65
50-Day Range: $14.40
▼
$16.00
52-Week Range: $11.32
▼
$16.86

Volume: 47,546 shs
Average Volume: 661,764 shs
Market Capitalization: $923.16 million

P/E Ratio: 6.70
Dividend Yield: N/A
Price Target: $22.50

Get Innoviva alerts:

Innoviva MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 55.4% Upside
$22.50 Price Target
Short Interest: Bearish
18.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.33
Upright™ Environmental Score
News Sentiment: 1.16
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

157th out of 913 stocks

Pharmaceutical Preparations Industry

55th out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
Innoviva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Innoviva has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
18.15% of the float of Innoviva has been sold short.
Short Interest Ratio / Days to Cover
Innoviva has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Innoviva has recently decreased by 12.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Innoviva does not currently pay a dividend.
Dividend Growth
Innoviva does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Innoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.
Environmental Sustainability
The Environmental Impact score for Innoviva is -0.33.

2.9

News and Social Media Coverage

News Sentiment
Innoviva has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Innoviva this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innoviva insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Innoviva is held by insiders.
Percentage Held by Institutions
99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Innoviva is 6.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of Innoviva is 6.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.70.
Price to Book Value per Share Ratio
Innoviva has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Innoviva Stock (NASDAQ:INVA)

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INVA Stock News Headlines

April 16, 2024 | americanbankingnews.com

Innoviva, Inc. (NASDAQ:INVA) Sees Significant Decline in Short Interest

March 8, 2024 | benzinga.com

Insider Decision Unfolding At Innoviva: Pavel Raifeld Exercises Options

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 4, 2024 | msn.com

Armata enters $35M credit agreement with Innoviva

February 29, 2024 | finance.yahoo.com

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

February 29, 2024 | businesswire.com

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

February 28, 2024 | msn.com

10 stocks you can bet on being inflation-proof

February 14, 2024 | finance.yahoo.com

Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 8, 2024 | morningstar.com

Innoviva Inc INVA

February 6, 2024 | morningstar.com

Cosmo Pharmaceuticals NV COPN

January 25, 2024 | stocknews.com

3 Lucrative Biotech Stock Buys for Success

January 8, 2024 | msn.com

Chart of the Day: Innoviva - Individual Investor Favorite

December 30, 2023 | finance.yahoo.com

Innoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three years

December 21, 2023 | uk.finance.yahoo.com

Innoviva, Inc. (INVA) stock historical prices & data – Yahoo Finance

December 11, 2023 | stocknews.com

Analyzing the Bullish Opportunities of 3 Biotech Stocks

November 27, 2023 | msn.com

Innoviva (INVA) Price Target Increased by 7.14% to 15.30

November 18, 2023 | finance.yahoo.com

Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc

November 14, 2023 | finance.yahoo.com

Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

November 3, 2023 | finance.yahoo.com

Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million

November 1, 2023 | finance.yahoo.com

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

November 1, 2023 | finance.yahoo.com

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

October 18, 2023 | finance.yahoo.com

Calculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)

October 9, 2023 | seekingalpha.com

Innoviva: A Lot Of Moving Parts

September 19, 2023 | finance.yahoo.com

Innoviva to Participate in the Cantor Global Healthcare Conference

September 18, 2023 | finance.yahoo.com

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

August 25, 2023 | finance.yahoo.com

Innoviva Appoints Stephen Basso as Chief Financial Officer

See More Headlines

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:INVA
Previous Symbol: NASDAQ:THRX
CUSIP: 88338T10
CIK: 1080014
Web: www.inva.com
Phone: (650) 238-9600
Fax: 650-827-8690
Employees: 112
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $22.50
High Stock Price Target: $22.50
Low Stock Price Target: $22.50
Potential Upside/Downside: +55.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.18
Trailing P/E Ratio: 6.64
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $179.72 million
Net Margins: 57.89%
Pretax Margin: 62.52%
Return on Equity: 30.37%
Return on Assets: 15.70%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 9.03
Quick Ratio: 7.96

Sales & Book Value

Annual Sales: $310.46 million
Price / Sales: 2.95
Cash Flow: $3.51 per share
Price / Cash Flow: 4.12
Book Value: $10.66 per share
Price / Book: 1.36

Miscellaneous

Outstanding Shares: 63,227,000
Free Float: 62,342,000
Market Cap: $915.53 million
Optionable: Optionable
Beta: 0.57

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Pavel Raifeld C.F.A. (Age 40)
Chief Executive Officer
Comp: $754.67k
Ms. Marianne Zhen CPA (Age 55)
Chief Accounting Officer & Secretary
Comp: $530.21k
Mr. Stephen Basso M.B.A. (Age 58)
Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INVA shares.
View INVA analyst ratings or view top-rated stocks.
What is Innoviva's stock price target for 2024?: 1 brokers have issued twelve-month price targets for Innoviva's shares. Their INVA share price targets range from $22.50 to $22.50. On average, they anticipate the company's stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 55.4% from the stock's current price.
View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.
How have INVA shares performed in 2024?: Innoviva's stock was trading at $16.04 at the beginning of 2024. Since then, INVA shares have decreased by 9.7% and is now trading at $14.48.
View the best growth stocks for 2024 here.
Are investors shorting Innoviva?: Innoviva saw a drop in short interest in March. As of March 31st, there was short interest totaling 11,330,000 shares, a drop of 13.0% from the March 15th total of 13,020,000 shares. Based on an average daily trading volume, of 681,300 shares, the days-to-cover ratio is presently 16.6 days. Approximately 18.2% of the shares of the stock are sold short.
View Innoviva's Short Interest.
When is Innoviva's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our INVA earnings forecast.
How were Innoviva's earnings last quarter?: Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Thursday, February, 29th. The biotechnology company reported $0.76 earnings per share for the quarter. The biotechnology company earned $85.84 million during the quarter. Innoviva had a net margin of 57.89% and a trailing twelve-month return on equity of 30.37%.

What ETFs hold Innoviva's stock?: ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Pharmaceuticals ETF (PJP), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Harbor Health Care ETF (MEDI), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco S&P SmallCap Health Care ETF (PSCH).
What other stocks do shareholders of Innoviva own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).
Who are Innoviva's major shareholders?: Innoviva's stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.22%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends.
How do I buy shares of Innoviva?: Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INVA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Innoviva (INVA) Stock Price, News & Analysis

Innoviva MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Innoviva Stock (NASDAQ:INVA)

INVA Stock Price History

INVA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

INVA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™